Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD) reported fiscal Q2 results for the period ended September 30, 2025 and provided a corporate update on clinical and research programs.

Key financials include $5.8M cash, a 48% reduction in operating expenses to ~$1.5M for the quarter, and an operating loss of $1.5M vs $2.8M year-ago. Clinical progress includes recruitment of Cohort 2 in the Australian oncology Hemopurifier trial and early biomarker changes observed in 3 initial participants. Collaboration with UCSF on Long COVID EV analysis and an evaluation of Hemopurifier compatibility with a simplified blood treatment system were also announced.

Positive

• Operating expenses down by 48% QoQ year-over-year
• Operating loss reduced to $1.5M from $2.8M prior-year quarter
• Cash balance of approximately $5.8M as of September 30, 2025
• Recruitment initiated for Cohort 2 of Australian oncology trial

Negative

• Cash on hand (~$5.8M) may be insufficient to support operations for the next 12 months without additional financing
• Clinical observations derive from 3 participants and are preliminary, limiting their evidentiary weight

Insights

Clinical and Financial Analyst

Aethlon shows cost cuts, small cash runway, and early clinical signals; trials remain exploratory and safety‑focused.

Operating discipline reduced quarterly expenses by 48%, lowering operating loss to 1.5M. Cash on hand stood at approximately 5.8M as of September 30, 2025, and Nasdaq compliance issues were resolved, maintaining listing status.

Clinical data remain preliminary. Recruitment for Cohort 2 in Australia has begun under an amended protocol allowing anti‑PD‑1 combinations. Small cohort observations reported decreases in certain extracellular vesicle (EV) subtypes, microRNA changes, and increases in some T cell measures after single 4‑hour treatments. The study's primary endpoint is safety and will enroll about 9–18 participants.

Dependencies and risks include limited sample sizes, early feasibility design, and the explicit statement that safety and effectiveness are unestablished. The cash balance implies limited runway absent new financing; operational improvements lower cash burn but do not confirm funding sufficiency beyond near term.

Watch for enrollment milestones and data from additional cohorts to assess reproducibility and dose response, any updates on PMA study design, and corporate financing actions within the next 6–12 months. Concrete near‑term items: Cohort 2 recruitment progress and the UCSF manuscript submission timing.

Clinical and research progress continues alongside substantial cost reductions.

Conference Call Today at 4:30 p.m. ET

SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments. 

Key Highlights

• Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.
• Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protocol.
• Scientific Advancement: Ongoing collaboration with UCSF on Long COVID research, with a manuscript in preparation for peer-reviewed journal.
• Technology Development: Initiated evaluation of Hemopurifier compatibility with a simplified blood treatment system
• Operational Efficiency: Operating expenses reduced by 48%, reflecting disciplined cost management.

Clinical and Corporate Update

Clinical Progress in Cancer Trial

Aethlon continues to advance its clinical, scientific, and operational initiatives in support of its mission to develop therapeutic devices for cancer and infectious diseases. Nasdaq compliance matters have been resolved, and the company remains listed on the Capital Market.

Recruitment has begun for the second cohort of the Australian oncology trial of the Hemopurifier® is underway under the amended protocol that allows patients receiving combination therapies with Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). The study is designed to evaluate safety, feasibility, and dose-finding in patients with solid tumors who have not responded to PD-1 therapy. Additional cohorts will examine whether sequential Hemopurifier treatments decrease extracellular vesicle (EV) concentrations and enhance the body's immune response against tumor cells.

As previously reported, the laboratory of Professor Georges Grau at the University of Sydney analyzed EVs and lymphocyte counts in samples from patients in the first cohort before and after Hemopurifier treatment. EVs are nanoparticles that are involved in cell-to-cell communication and are implicated in the spread of cancer (metastasis), growth of new blood vessels to the tumor, (angiogenesis), cell death (apoptosis), and inhibition of the body's T cells, which are important for killing tumor cells. Two of the three participants in the trial showed decreases in large EVs, also known as microvesicles, following the Hemopurifier treatment. Decreases were observed in large and small platelet-derived EVs in two of the three patients. We observed decreases in the subset of large EVs carrying PD-L1 in all three participants during the Hemopurifier treatment. Persistently elevated counts of EVs with PD-L1 have been associated with lack of response to anti-PD-1 agents.

Decreases were observed in seven out of ten microRNAs examined in two of the three participants following a single 4-hour Hemopurifier treatment. MicroRNAs are one component of the cargo of extracellular vesicles, previously reported to promote cancer growth and metastasis.

Improvements in laboratory ratios associated with responses to immunotherapy including Neutrophil, Lymphocyte, Monocyte, Albumin and Systemic Immune-Inflammation were observed in at least two participants after a single 4-hour treatment. Increases were noted in total T cell numbers, CD8 and CD4 T cell subsets, and tumor specific T cells (CD137 +ve) in participants following Hemopurifier treatment without a consistent pattern in terms of timing of improvement.

Additional data from the subsequent two cohorts will help determine whether these observations are reproducible, and whether there is a dose response with additional Hemopurifier treatments in terms of the magnitude and duration of the changes.

We believe the unmet need remains significant: currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors are believed to contribute to both cancer progression and resistance to anti-PD-1 therapies.

The study's primary endpoint is safety. The study will enroll approximately 9 to 18 participants. Eligible patients with solid tumors with stable or progressive disease receive escalating doses of Hemopurifier treatment across sequential cohorts - one, two, and three Hemopurifier treatments administered over the course of a single week. In addition to evaluating safety, the study is designed to assess whether reducing the concentration of EVs may improve the body's own natural ability to attack tumor cells. These exploratory findings are expected to inform the design of future efficacy and safety trials, including a Premarket Approval (PMA) study.

Scientific Collaboration in Long COVID Research and Technology Development

Analysis of EV cargo from Long COVID patient samples continues in collaboration with the University of California, San Francisco (UCSF). These studies build on prior findings showing that the Hemopurifier can bind and remove large and small EVs from Long COVID patients. A manuscript detailing these results is being prepared for submission to a peer-reviewed journal.

We also initiated an evaluation to study the compatibility of the Hemopurifier with an alternative blood treatment system that uses a single small-lumen catheter and simplified blood pump compared to traditional hemodialysis setups. This research could lead to simplified system for performing Hemopurifier treatments in Oncology units in the future.

Operational Achievements

Operating expenses decreased by 48% during the quarter, reflecting the Company's ongoing efforts to reduce costs while advancing its clinical and research programs.

"We remain focused on executing our clinical and research strategy while maintaining operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Our ongoing trial progress, research collaborations, and technology initiatives continue to support our long-term goal of developing therapeutic solutions for cancer and life-threatening infectious diseases."

Financial Results for the Fiscal Second Quarter Ended September 30, 2025

As of September 30, 2025, Aethlon had a cash balance of approximately $5.8 million.

Consolidated operating expenses for the three months ended September 30, 2025 were approximately $1.5 million, down by approximately $1.4 million or 48%, from $2.9 million in the same period in 2024. The decreases were reflected across payroll, general and administrative and professional fees.

• Payroll and related expenses decreased by approximately $778,000, reflecting lower headcount, reduced bonus accruals, and absence of prior-year severance charges.
• General and Administrative expenses declined by approximately $437,000 driven by lower clinical trial costs, in part due to a $218,000 R&D tax incentive, as well as reductions in supplies, insurance, and other operational costs.
• Professional fees decreased by approximately $177,000, mainly from reduced investor relations and contract labor expenses, partially offset by higher legal, tax, audit and financial services costs.

As a result of these factors, operating loss for the quarter decreased to $1.5 million compared to $2.8 million in the prior-year period.

Other income totaled $22,730 for the three months ended September 30, 2025, compared to $95,146 in the prior-year period. In both quarters, other income was primarily interest income earned on cash balances.

The consolidated balance sheets for September 30, 2025 and March 31, 2025, along with the consolidated statements of operations for the three and six months ended September 30, 2025 and 2024, are included at the end of this release.

Conference Call

Management will host a conference call today, Wednesday, November 12, 2025, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/1005d2109f4. Please note that registered participants will receive their dial-in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through December 12, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 1454680.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia, within expected timelines; the timing, scope, design, and potential outcomes of such studies; the Company's ability to manufacture the Hemopurifier for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the nest 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
ASSETS
			September 30, 2025		March 31, 2025
CURRENT ASSETS
	Cash and cash equivalents		$                       5,853,493		$                                 5,501,261
	Australian research and development tax incentive receivable		218,314		-
	Prepaid expenses and other current assets		182,072		448,539
	TOTAL CURRENT ASSETS		6,253,879		5,949,800
	Property and equipment, net		513,992		676,220
	Operating lease right-of-use  asset		456,496		601,846
	Patents, net		275		550
	Restricted cash		98,448		97,813
	Deposits		-		33,305
	TOTAL ASSETS		$                   7,323,090		$                           7,359,534
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
	Accounts payable		$                          570,792		$                                    534,524
	Due to related parties		248,454		579,565
	Operating lease liability, current portion		324,656		313,033
	Other current liabilities		261,095		472,164
	TOTAL CURRENT LIABILITIES		1,404,997		1,899,286
	Operating lease liability, less current portion		172,116		336,718
	TOTAL LIABILITIES		1,577,113		2,236,004
STOCKHOLDERS' EQUITY
	Common stock, par value $0.001 per share; 6,000,000 shares authorized as of September      30, 2025 and March 31, 2025; 761,318 and 258,531 shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively
			761		259
	Additional paid-in capital		176,975,368		173,095,221
	Accumulated other comprehensive loss		(26,377)		(17,133)
	Accumulated deficit		(171,203,775)		(167,954,817)
	TOTAL STOCKHOLDERS' EQUITY		5,745,977		5,123,530
	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$                   7,323,090		$                           7,359,534

 

AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Statements of Operations and Comprehensive Loss
For the three and six month periods ended September 30, 2025 and 2024
		Three Months		Three Months		Six Months		Six Months
		Ended 9/30/25		Ended 9/30/24		Ended 9/30/25		Ended 9/30/24
OPERATING EXPENSES
Professional fees		393,796		570,845		869,828		1,184,927
Payroll and related expenses		594,611		1,372,899		1,175,611		2,627,701
General and administrative		521,423		958,375		1,256,781		1,709,228
Total operating expenses		1,509,830		2,902,119		3,302,220		5,521,856
OPERATING LOSS		(1,509,830)		(2,902,119)		(3,302,220)		(5,521,856)
INTEREST INCOME, NET		22,730		95,146		53,262		143,442
NET LOSS		$(1,487,100)		$(2,806,973)		$(3,248,958)		$(5,378,414)
OTHER COMPREHENSIVE (LOSS)/INCOME		(4,000)		3,804		(9,244)		2,971
COMPREHENSIVE LOSS		$(1,491,100)		$(2,803,169)		$(3,258,202)		$(5,375,443)
Basic and diluted loss per share attributable to
common stockholders		$          (3.74)		$        (16.11)		$        (10.65)		$        (40.15)
Basic and diluted weighted average number of
common shares outstanding  - basic and diluted		397,513		174,220		304,960		133,944

 

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-q2-2025-financial-results-and-corporate-update-302612307.html

SOURCE Aethlon Medical, Inc.

FAQ

What were Aethlon Medical (AEMD) fiscal Q2 2025 operating expenses and change?

Operating expenses for Q2 FY2025 were approximately $1.5M, down ~48% from $2.9M in the prior-year period.

How much cash did Aethlon (AEMD) report on September 30, 2025?

Aethlon reported approximately $5.8M in cash and cash equivalents as of September 30, 2025.

What clinical progress did Aethlon (AEMD) announce on November 12, 2025?

The company began recruitment for Cohort 2 of its Australian oncology Hemopurifier trial under an amended protocol.

What early Hemopurifier trial results did Aethlon (AEMD) report?

In the initial 3 participants, decreases were observed in several large and small extracellular vesicle subsets and some immune cell markers after a single 4-hour treatment; results are preliminary.

Is Aethlon (AEMD) collaborating on Long COVID research?

Yes; Aethlon is collaborating with UCSF on analysis of EV cargo from Long COVID samples and preparing a manuscript.

Will Aethlon (AEMD) host a conference call about Q2 2025 results and when?

Yes; management hosted a conference call on November 12, 2025 at 4:30 p.m. ET with a replay available through December 12, 2025.